Ensign Peak Advisors’s Maravai LifeSciences MRVI Stock Holding History

Ensign Peak Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-37,150	Closed	-$202K	–	1709
2024 Q4	$202K	Hold	37,150	–	–	﹤0.01%	1694
2024 Q3	$309K	Hold	37,150	–	–	﹤0.01%	1671
2024 Q2	$266K	Buy	+37,150	New	+$321K	﹤0.01%	1686
2022 Q4	–	Sell	-31,160	Closed	-$796K	–	2063
2022 Q3	$796K	Sell	31,160 -3,280	-10%	-$82.3K	﹤0.01%	1200
2022 Q2	$978K	Hold	34,440	–	–	﹤0.01%	1120
2022 Q1	$1.22M	Buy	34,440 +7,280	+27%	+$244K	﹤0.01%	1092
2021 Q4	$1.14M	Buy	+27,160	New	+$1.1M	﹤0.01%	1208

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's MRVI Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 37,150 shares — an estimated $202K sold.

Ensign Peak Advisors first reported a position in MRVI in Q4 2021 and held it in 7 quarters. The position peaked at $1.22M in Q1 2022. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

Ensign Peak Advisors reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
Ensign Peak Advisors sold 37,150 Maravai LifeSciences shares in Q1 2025, an estimated $202K.
Ensign Peak Advisors first reported a position in Maravai LifeSciences in Q4 2021 and held it in 7 quarters.
Ensign Peak Advisors's Maravai LifeSciences position peaked at $1.22M in Q1 2022.
184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.